The compound is a 3CL protease inhibitor on COVID-19 virus (i.e. SARS-CoV-2), which is inhibiting the first step of viral replication after the virus fusing into the cell. The project has had lead compounds and is currently under lead optimization stage. Structural modifications for better enzyme and antiviral activities are under process.